UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 76 filers reported holding UROGEN PHARMA LTD in Q1 2019. The put-call ratio across all filers is 0.32 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $187,000 | -6.0% | 22,801 | 0.0% | 0.00% | +50.0% |
| Q1 2022 | $199,000 | -50.7% | 22,801 | -46.4% | 0.00% | -33.3% |
| Q4 2021 | $404,000 | -43.8% | 42,501 | 0.0% | 0.00% | -40.0% |
| Q3 2021 | $719,000 | +10.8% | 42,501 | 0.0% | 0.01% | 0.0% |
| Q2 2021 | $649,000 | -21.6% | 42,501 | 0.0% | 0.01% | -37.5% |
| Q1 2021 | $828,000 | +95.7% | 42,501 | +80.8% | 0.01% | 0.0% |
| Q4 2020 | $423,000 | -6.6% | 23,501 | 0.0% | 0.01% | -27.3% |
| Q3 2020 | $453,000 | -26.2% | 23,501 | 0.0% | 0.01% | -38.9% |
| Q2 2020 | $614,000 | +46.5% | 23,501 | 0.0% | 0.02% | -10.0% |
| Q1 2020 | $419,000 | -52.0% | 23,501 | -10.2% | 0.02% | -20.0% |
| Q4 2019 | $873,000 | +40.8% | 26,172 | 0.0% | 0.02% | +4.2% |
| Q3 2019 | $620,000 | -33.4% | 26,172 | +1.1% | 0.02% | -38.5% |
| Q2 2019 | $931,000 | +2.1% | 25,892 | +4.8% | 0.04% | -7.1% |
| Q1 2019 | $912,000 | -14.2% | 24,698 | 0.0% | 0.04% | -10.6% |
| Q4 2018 | $1,063,000 | – | 24,698 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,620,545 | $36,713,835 | 6.69% |
| Wildcat Capital Management, LLC | 495,606 | $6,943,440 | 2.79% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 508,883 | $7,129,451 | 2.16% |
| Opaleye Management Inc. | 320,000 | $4,483,200 | 1.46% |
| AlphaCentric Advisors LLC | 165,000 | $2,311,650 | 1.31% |
| Soleus Capital Management, L.P. | 372,000 | $5,211,720 | 0.48% |
| EAM Investors, LLC | 170,523 | $2,389,027 | 0.46% |
| RA Capital Management | 1,483,697 | $20,786,595 | 0.41% |
| Parkman Healthcare Partners LLC | 145,311 | $2,035,807 | 0.37% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 | $32,265,464 | 0.29% |